相关实验视频
Updated: Jul 18, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.9K
连接胰岛素笔在糖尿病管理中的优缺点
Kathryn Lingen1, Talia Pikounis1, Natalie Bellini2
1Close Concerns, San Francisco, California, USA.
Endocrine connections
|August 23, 2023
概括
连接的胰岛素笔和笔盖提供了先进的糖尿病管理功能,但由于意识和培训障碍,采用率仍然很低. 改善数据和教育可以提高许多糖尿病患者的血糖控制.
科学领域:
- 内分泌学 在内分泌学.
- 糖尿病 技术 技术
- 数字健康数字健康
背景情况:
- 胰岛素治疗对于糖尿病管理至关重要,但许多患者经历了低于最佳的血糖控制.
- 连接的胰岛素设备,包括笔和笔盖,代表了胰岛素输送的最新进展.
- 尽管有技术进步,但仍有重大障碍阻碍了这些创新工具的广泛采用.
研究的目的:
- 审查有关连接胰岛素笔和笔盖的文献.
- 阐明这些先进的糖尿病管理设备的临床好处和缺点.
- 确定限制连接胰岛素技术普及的因素.
主要方法:
- 关于连接的胰岛素笔和笔盖的文献评论.
- 对设备特征,监管批准和临床益处的分析.
- 审查采用障碍和潜在解决方案的障碍.
主要成果:
- 连接设备提供诸如自动剂量记录,机载胰岛素跟踪和错过剂量警报等功能.
- 目前连接的胰岛素笔和盖的使用率很低.
- 障碍包括缺乏医疗保健专业人员的认识,处方员培训需求和设备设置复杂性.
结论:
- 连接的胰岛素笔和帽子可以缓解糖尿病管理,并使数据驱动的方法.
- 通过教育克服采用障碍,并展示血糖结果是必不可少的.
- 这些设备对于不适合使用胰岛素或自动胰岛素输送系统的人来说具有潜力.
相关概念视频
Insulin Formulations: Types and Delivery
226
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
226
Insulin: Dosing Regimen and Adverse Effects
205
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
205
Diabetes Mellitus: Overview and Type I Subtype
2.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K
Diabetes: Management and Pharmacotherapy
310
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
310
Insulin: Biosynthesis, Chemistry, and Preparation
428
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
428
Oral Hypoglycemic Agents: Glinides
184
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
184

